Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study ID
- NCT06201715
- Status
- Unknown
Conditions
- Itch
- Prurigo Nodularis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tofacitinib 5 MG — DRUG5mg tofacitinib tablet twice daily
Study Details
The goal is to evaluate the efficacy and safety of tofacitinib in treating refractory prurigo nodularis.The main questions it aims to answer are 1. whether tofacitinib is effective in treating prurigo nodularis in the longpterm. 2. whether tofacitinib is safe in prurigo nodularis patients in the longpterm.
Key Dates
- Start date
- May 1, 2024
- Status verified
- Sep 2023
- Primary completion
- Jun 30, 2025
- Completion
- Dec 30, 2025
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: tofacitinib
Primary Outcome Measure
Investigator's global assessment [ Time Frame: up to 12 weeks ]
Central Contacts
- Ru Dai+8615982215914
Related Studies
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisPHASE3 · Recruiting · Sanofi · Palo Alto, California
- Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in AdultsRecruiting · Galderma R&D · Birmingham, Alabama
- Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.PHASE4 · Not Yet Recruiting · Integrative Skin Science and Research · Sacramento, California